The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population

The aim of this study was to estimate the contribution of deleterious mutations in BRCA1, BRCA2, MLH1, MSH2, MSH6 and PMS2 to invasive epithelial ovarian cancer (EOC) in the population. The coding sequence and splice site boundaries of all six genes were amplified in germline DNA from 2240 invasive...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Human molecular genetics Ročník 23; číslo 17; s. 4703
Hlavní autori:	Song, Honglin, Cicek, Mine S, Dicks, Ed, Harrington, Patricia, Ramus, Susan J, Cunningham, Julie M, Fridley, Brooke L, Tyrer, Jonathan P, Alsop, Jennifer, Jimenez-Linan, Mercedes, Gayther, Simon A, Goode, Ellen L, Pharoah, Paul D P
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England 01.09.2014
Predmet:	Adult Age of Onset Aged BRCA1 Protein - genetics BRCA2 Protein - genetics DNA Mismatch Repair - genetics Female Genetic Predisposition to Disease Germ-Line Mutation - genetics Humans Middle Aged Mutation, Missense - genetics Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Risk Factors Young Adult
ISSN:	1460-2083, 1460-2083
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	The aim of this study was to estimate the contribution of deleterious mutations in BRCA1, BRCA2, MLH1, MSH2, MSH6 and PMS2 to invasive epithelial ovarian cancer (EOC) in the population. The coding sequence and splice site boundaries of all six genes were amplified in germline DNA from 2240 invasive EOC cases and 1535 controls. Barcoded fragment libraries were sequenced using the Illumina GAII or HiSeq and sequence data for each subject de-multiplexed prior to interpretation. GATK and Annovar were used for variant detection and annotation. After quality control 2222 cases (99.2%) and 1528 controls (99.5%) were included in the final analysis. We identified 193 EOC cases (8.7%) carrying a deleterious mutation in at least one gene compared with 10 controls (0.65%). Mutations were most frequent in BRCA1 and BRCA2, with 84 EOC cases (3.8%) carrying a BRCA1 mutation and 94 EOC cases (4.2%) carrying a BRCA2 mutation. The combined BRCA1 and BRCA2 mutation prevalence was 11% in high-grade serous disease. Seventeen EOC cases carried a mutation in a mismatch repair gene, including 10 MSH6 mutation carriers (0.45%) and 4 MSH2 mutation carriers (0.18%). At least 1 in 10 women with high-grade serous EOC has a BRCA1 or BRCA2 mutation. The development of next generation sequencing technologies enables rapid mutation screening for multiple susceptibility genes at once, suggesting that routine clinical testing of all incidence cases should be considered.
AbstractList	The aim of this study was to estimate the contribution of deleterious mutations in BRCA1, BRCA2, MLH1, MSH2, MSH6 and PMS2 to invasive epithelial ovarian cancer (EOC) in the population. The coding sequence and splice site boundaries of all six genes were amplified in germline DNA from 2240 invasive EOC cases and 1535 controls. Barcoded fragment libraries were sequenced using the Illumina GAII or HiSeq and sequence data for each subject de-multiplexed prior to interpretation. GATK and Annovar were used for variant detection and annotation. After quality control 2222 cases (99.2%) and 1528 controls (99.5%) were included in the final analysis. We identified 193 EOC cases (8.7%) carrying a deleterious mutation in at least one gene compared with 10 controls (0.65%). Mutations were most frequent in BRCA1 and BRCA2, with 84 EOC cases (3.8%) carrying a BRCA1 mutation and 94 EOC cases (4.2%) carrying a BRCA2 mutation. The combined BRCA1 and BRCA2 mutation prevalence was 11% in high-grade serous disease. Seventeen EOC cases carried a mutation in a mismatch repair gene, including 10 MSH6 mutation carriers (0.45%) and 4 MSH2 mutation carriers (0.18%). At least 1 in 10 women with high-grade serous EOC has a BRCA1 or BRCA2 mutation. The development of next generation sequencing technologies enables rapid mutation screening for multiple susceptibility genes at once, suggesting that routine clinical testing of all incidence cases should be considered. The aim of this study was to estimate the contribution of deleterious mutations in BRCA1, BRCA2, MLH1, MSH2, MSH6 and PMS2 to invasive epithelial ovarian cancer (EOC) in the population. The coding sequence and splice site boundaries of all six genes were amplified in germline DNA from 2240 invasive EOC cases and 1535 controls. Barcoded fragment libraries were sequenced using the Illumina GAII or HiSeq and sequence data for each subject de-multiplexed prior to interpretation. GATK and Annovar were used for variant detection and annotation. After quality control 2222 cases (99.2%) and 1528 controls (99.5%) were included in the final analysis. We identified 193 EOC cases (8.7%) carrying a deleterious mutation in at least one gene compared with 10 controls (0.65%). Mutations were most frequent in BRCA1 and BRCA2, with 84 EOC cases (3.8%) carrying a BRCA1 mutation and 94 EOC cases (4.2%) carrying a BRCA2 mutation. The combined BRCA1 and BRCA2 mutation prevalence was 11% in high-grade serous disease. Seventeen EOC cases carried a mutation in a mismatch repair gene, including 10 MSH6 mutation carriers (0.45%) and 4 MSH2 mutation carriers (0.18%). At least 1 in 10 women with high-grade serous EOC has a BRCA1 or BRCA2 mutation. The development of next generation sequencing technologies enables rapid mutation screening for multiple susceptibility genes at once, suggesting that routine clinical testing of all incidence cases should be considered.The aim of this study was to estimate the contribution of deleterious mutations in BRCA1, BRCA2, MLH1, MSH2, MSH6 and PMS2 to invasive epithelial ovarian cancer (EOC) in the population. The coding sequence and splice site boundaries of all six genes were amplified in germline DNA from 2240 invasive EOC cases and 1535 controls. Barcoded fragment libraries were sequenced using the Illumina GAII or HiSeq and sequence data for each subject de-multiplexed prior to interpretation. GATK and Annovar were used for variant detection and annotation. After quality control 2222 cases (99.2%) and 1528 controls (99.5%) were included in the final analysis. We identified 193 EOC cases (8.7%) carrying a deleterious mutation in at least one gene compared with 10 controls (0.65%). Mutations were most frequent in BRCA1 and BRCA2, with 84 EOC cases (3.8%) carrying a BRCA1 mutation and 94 EOC cases (4.2%) carrying a BRCA2 mutation. The combined BRCA1 and BRCA2 mutation prevalence was 11% in high-grade serous disease. Seventeen EOC cases carried a mutation in a mismatch repair gene, including 10 MSH6 mutation carriers (0.45%) and 4 MSH2 mutation carriers (0.18%). At least 1 in 10 women with high-grade serous EOC has a BRCA1 or BRCA2 mutation. The development of next generation sequencing technologies enables rapid mutation screening for multiple susceptibility genes at once, suggesting that routine clinical testing of all incidence cases should be considered.
Author	Alsop, Jennifer Dicks, Ed Pharoah, Paul D P Song, Honglin Tyrer, Jonathan P Jimenez-Linan, Mercedes Gayther, Simon A Goode, Ellen L Fridley, Brooke L Cicek, Mine S Ramus, Susan J Cunningham, Julie M Harrington, Patricia
Author_xml	– sequence: 1 givenname: Honglin surname: Song fullname: Song, Honglin email: hs310@medschl.cam.ac.uk organization: CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK, hs310@medschl.cam.ac.uk – sequence: 2 givenname: Mine S surname: Cicek fullname: Cicek, Mine S organization: Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA – sequence: 3 givenname: Ed surname: Dicks fullname: Dicks, Ed organization: CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK – sequence: 4 givenname: Patricia surname: Harrington fullname: Harrington, Patricia organization: CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK – sequence: 5 givenname: Susan J surname: Ramus fullname: Ramus, Susan J organization: Department of Preventive Medicine, Keck School of Medicine, USC/Norris Comprehensive Cancer Center, University of Southern California, CA, USA – sequence: 6 givenname: Julie M surname: Cunningham fullname: Cunningham, Julie M organization: Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA – sequence: 7 givenname: Brooke L surname: Fridley fullname: Fridley, Brooke L organization: Department of Biostatistics, University of Kansas Medical Center, Kansas, USA and – sequence: 8 givenname: Jonathan P surname: Tyrer fullname: Tyrer, Jonathan P organization: CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK – sequence: 9 givenname: Jennifer surname: Alsop fullname: Alsop, Jennifer organization: CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK – sequence: 10 givenname: Mercedes surname: Jimenez-Linan fullname: Jimenez-Linan, Mercedes organization: Department of Histopathology, Addenbrooke's Hospital, Cambridge, UK – sequence: 11 givenname: Simon A surname: Gayther fullname: Gayther, Simon A organization: Department of Preventive Medicine, Keck School of Medicine, USC/Norris Comprehensive Cancer Center, University of Southern California, CA, USA – sequence: 12 givenname: Ellen L surname: Goode fullname: Goode, Ellen L organization: Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA – sequence: 13 givenname: Paul D P surname: Pharoah fullname: Pharoah, Paul D P organization: CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/24728189$$D View this record in MEDLINE/PubMed
BookMark	eNpNkMtOwzAQRS1URB-w4QOQlywojV9xsiwVL6kSEirryLEnrVFiB8dBYs-Hk5YisbqzOPdoZqZo5LwDhC5JckuSnC12zXZhTE8kPUETwtNkTpOMjf7NYzTtuvckISln8gyNKZc0I1k-Qd-bHWDtXQy27KP1DvsKG6ghQrC-7_AWQlNbB7jpo9oDHbYO372uluTmEBQrZ3AcNI3tGhX1DgdolQ1D1UGHo8f-UwWrHNbKaQj7_h5vfdvXB-U5Oq1U3cHFMWfo7eF-s3qar18en1fL9VxzKeM8z5VQQudgIC0zo9JSCm1oxhKdgpEl08IowomoOKMpKJEB44bIlOWSSV7RGbr-9bbBf_TQxWJYWUNdKwfDrQURgjAquaADenVE-7IBU7TBNip8FX-foz_l73K7
CitedBy_id	crossref_primary_10_1097_CEJ_0000000000000931 crossref_primary_10_1016_j_critrevonc_2022_103626 crossref_primary_10_1093_jnci_djae328 crossref_primary_10_1159_000538948 crossref_primary_10_1038_nrc4019 crossref_primary_10_1111_jog_13287 crossref_primary_10_1016_j_ejcsup_2020_02_001 crossref_primary_10_3390_cancers13174344 crossref_primary_10_1016_j_jval_2018_02_009 crossref_primary_10_1038_s41416_023_02263_5 crossref_primary_10_3390_jpm11020149 crossref_primary_10_1093_nar_gkx1280 crossref_primary_10_2217_fon_2016_0189 crossref_primary_10_1007_s40944_017_0150_0 crossref_primary_10_1093_jnci_djv214 crossref_primary_10_1016_j_ejca_2019_10_018 crossref_primary_10_1186_s13053_016_0052_7 crossref_primary_10_1186_s13048_023_01119_z crossref_primary_10_1016_j_ajhg_2024_04_011 crossref_primary_10_1038_s41598_023_33857_x crossref_primary_10_3389_fcell_2021_701073 crossref_primary_10_1016_j_heliyon_2024_e37288 crossref_primary_10_1038_s41416_020_0822_x crossref_primary_10_1007_s10689_020_00179_0 crossref_primary_10_3390_cancers12103046 crossref_primary_10_1002_ijc_33378 crossref_primary_10_1016_j_ygyno_2018_09_030 crossref_primary_10_1136_jmedgenet_2015_103077 crossref_primary_10_1007_s10897_016_9996_z crossref_primary_10_3390_cancers15020448 crossref_primary_10_5306_wjco_v10_i11_358 crossref_primary_10_1007_s10689_016_9919_z crossref_primary_10_2217_fon_15_278 crossref_primary_10_1136_ijgc_2020_001536 crossref_primary_10_1093_jnci_djv347 crossref_primary_10_3390_cimb46050281 crossref_primary_10_1016_j_currproblcancer_2017_02_009 crossref_primary_10_36290_xon_2017_043 crossref_primary_10_1136_jmedgenet_2019_106739 crossref_primary_10_1038_s10038_019_0562_z crossref_primary_10_3390_genes10110882 crossref_primary_10_1002_pros_24721 crossref_primary_10_1002_ijc_30633 crossref_primary_10_1093_carcin_bgv138 crossref_primary_10_1016_j_gore_2022_101028 crossref_primary_10_1186_s12885_017_3599_4 crossref_primary_10_1080_01443615_2022_2111253 crossref_primary_10_5858_arpa_2015_0457_RA crossref_primary_10_1016_j_ejca_2016_03_009 crossref_primary_10_1136_jmedgenet_2017_105195 crossref_primary_10_3390_cancers14163888 crossref_primary_10_3390_ijerph19138113 crossref_primary_10_1038_s41467_020_15461_z crossref_primary_10_3389_fonc_2022_835581 crossref_primary_10_1016_j_bpobgyn_2016_10_017 crossref_primary_10_1158_1078_0432_CCR_14_2497 crossref_primary_10_1159_000535012 crossref_primary_10_1186_s13048_020_00753_1 crossref_primary_10_1158_2159_8290_CD_19_1485 crossref_primary_10_1007_s12325_016_0281_1 crossref_primary_10_1038_ejhg_2015_196 crossref_primary_10_1016_j_genrep_2019_100380 crossref_primary_10_1038_srep14800 crossref_primary_10_1111_cge_13566 crossref_primary_10_1038_s41431_020_0692_y crossref_primary_10_1186_s12885_019_5829_4 crossref_primary_10_1016_j_ejim_2016_03_010 crossref_primary_10_1136_jmedgenet_2017_104947 crossref_primary_10_1007_s12282_020_01148_2 crossref_primary_10_1016_j_gim_2023_100898 crossref_primary_10_3389_fonc_2019_01549 crossref_primary_10_3892_ol_2019_9950 crossref_primary_10_1016_j_ygyno_2017_10_001 crossref_primary_10_1016_j_ygyno_2017_08_030 crossref_primary_10_1186_s12885_024_12246_1 crossref_primary_10_3892_ol_2019_11019 crossref_primary_10_1002_jgc4_1684 crossref_primary_10_1186_s13048_018_0424_x crossref_primary_10_7759_cureus_42439 crossref_primary_10_1016_j_ygyno_2022_12_008 crossref_primary_10_1038_s41431_025_01786_0 crossref_primary_10_1002_cam4_3383 crossref_primary_10_1002_ijc_34165 crossref_primary_10_1093_jnci_djac160 crossref_primary_10_1097_AOG_0000000000002580 crossref_primary_10_3389_fonc_2023_1227864 crossref_primary_10_1016_j_cca_2024_119992 crossref_primary_10_1016_j_gyobfe_2015_02_014 crossref_primary_10_1038_s41598_023_50151_y crossref_primary_10_1186_s12881_017_0448_x crossref_primary_10_1200_JCO_2015_61_2408 crossref_primary_10_1111_ajco_13116 crossref_primary_10_1080_07357907_2025_2524560 crossref_primary_10_1136_jmedgenet_2016_103902 crossref_primary_10_1038_s41598_018_24286_2
ContentType	Journal Article
Copyright	The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Copyright_xml	– notice: The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1093/hmg/ddu172
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Biology
EISSN	1460-2083
ExternalDocumentID	24728189
Genre	Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: Cancer Research UK grantid: C1005/A12677 – fundername: NCI NIH HHS grantid: P50 CA136393 – fundername: Cancer Research UK grantid: 12677 – fundername: NCI NIH HHS grantid: R01 CA122443 – fundername: Cancer Research UK grantid: C490/A10119 – fundername: Cancer Research UK grantid: 10124 – fundername: Cancer Research UK grantid: C490/A10124 – fundername: Cancer Research UK grantid: 16561 – fundername: NCI NIH HHS grantid: R01 CA178535 – fundername: NCI NIH HHS grantid: P50-CA136393
GroupedDBID	--- -DZ -E4 .2P .I3 .XZ .ZR 0R~ 18M 1TH 29I 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 70D AABZA AACZT AAIMJ AAJKP AAJQQ AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAVLN ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABMNT ABNHQ ABNKS ABPQP ABPTD ABQLI ABVGC ABWST ABXVV ABXZS ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ADBBV ADEYI ADEZT ADFTL ADGKP ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZTZ ADZXQ AEGPL AEGXH AEJOX AEKSI AELWJ AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFGWE AFIYH AFOFC AFYAG AGINJ AGKEF AGORE AGQXC AGSYK AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP AKHUL AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ARIXL ATGXG AXUDD AYOIW BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BSWAC BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K EBS ECM EE~ EIF EJD EMOBN F5P F9B FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IH2 IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z ML0 N9A NGC NLBLG NOMLY NOYVH NPM NU- NVLIB O9- OAWHX OBC OBOKY OBS OCZFY ODMLO OEB OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX ROZ RUSNO RW1 RXO SJN TEORI TJX TLC TMA TR2 W8F WOQ X7H XSW YAYTL YKOAZ YXANX ZKX ~91 7X8
ID	FETCH-LOGICAL-c477t-99a5a5c9ede6b8da6b75cd2830c6ed7b3c5da1415f4326ea58e34d176397374f2
IEDL.DBID	7X8
ISICitedReferencesCount	117
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000340238200019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1460-2083
IngestDate	Thu Oct 02 05:23:31 EDT 2025 Mon Jul 21 06:05:46 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	17
Language	English
License	The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c477t-99a5a5c9ede6b8da6b75cd2830c6ed7b3c5da1415f4326ea58e34d176397374f2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://academic.oup.com/hmg/article-pdf/23/17/4703/2206466/ddu172.pdf
PMID	24728189
PQID	1551327452
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1551327452 pubmed_primary_24728189
PublicationCentury	2000
PublicationDate	2014-09-01
PublicationDateYYYYMMDD	2014-09-01
PublicationDate_xml	– month: 09 year: 2014 text: 2014-09-01 day: 01
PublicationDecade	2010
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Human molecular genetics
PublicationTitleAlternate	Hum Mol Genet
PublicationYear	2014
SSID	ssj0016437
Score	2.491622
Snippet	The aim of this study was to estimate the contribution of deleterious mutations in BRCA1, BRCA2, MLH1, MSH2, MSH6 and PMS2 to invasive epithelial ovarian...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	4703
SubjectTerms	Adult Age of Onset Aged BRCA1 Protein - genetics BRCA2 Protein - genetics DNA Mismatch Repair - genetics Female Genetic Predisposition to Disease Germ-Line Mutation - genetics Humans Middle Aged Mutation, Missense - genetics Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Risk Factors Young Adult
Title	The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population
URI	https://www.ncbi.nlm.nih.gov/pubmed/24728189 https://www.proquest.com/docview/1551327452
Volume	23
WOSCitedRecordID	wos000340238200019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV27TsMwFLWAAmLhUV7lJSMxYpU0ThxPqFRULK0qBFK3yM-2Q5OStJXY-XCuk5ROSEgsyRJHsXNyfex7cw5CdzZUmjOhCTeeIZSJgAjg6SSUVlqtPB1JWZhNsH4_Gg75oNpwy6uyylVMLAK1TpXbI28WTiSwhApaj7MP4lyjXHa1stDYRDUfqIxDNRuuswguKVX-XfQAaIj8lTwp95vj6aip9cIrlIF_oZbFFNM9-O_DHaL9ilzidomGI7RhkjraKe0mP-tot1cl0o_RF8ADF2Xqld8VTi12njhOujld5HgEEdsxUDxdlMn6HE8S_PTaaXv3xamFRaIx0EcMSAHaq8Y4g6ltkkFTCJ94nuJ0CQtxkWDlkJW59u7y2Y9l2Al67z6_dV5IZchAFGVsTjgXgQgUN9qEMtIilCxQ2kmIqdBoJn0VaOEBJbAUWKERQWR8qj3mkoc-o7Z1iraSNDHnCGuqgLkZYalWTrJehFQCc4XbiBBWMbyBblcjHUM3XBZDJAb6H6_HuoHOytcVz0pljrhFmVO34hd_aH2J9oD80LJe7ArVLHzu5hptq-V8kmc3BZLg2B_0vgEI3dXZ
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+contribution+of+deleterious+germline+mutations+in+BRCA1%2C+BRCA2+and+the+mismatch+repair+genes+to+ovarian+cancer+in+the+population&rft.jtitle=Human+molecular+genetics&rft.au=Song%2C+Honglin&rft.au=Cicek%2C+Mine+S&rft.au=Dicks%2C+Ed&rft.au=Harrington%2C+Patricia&rft.date=2014-09-01&rft.eissn=1460-2083&rft.volume=23&rft.issue=17&rft.spage=4703&rft_id=info:doi/10.1093%2Fhmg%2Fddu172&rft_id=info%3Apmid%2F24728189&rft_id=info%3Apmid%2F24728189&rft.externalDocID=24728189
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2083&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2083&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2083&client=summon